Illumina Acquires SomaLogic from Standard BioTools

Standard BioTools Acquires Sengenics from Summa Equity

November 21, 2024

Biotechnology

Standard BioTools Inc. has acquired Sengenics Corporation Pte Ltd, a Summa Equity portfolio company, to broaden its proteomics and antibody‑profiling capabilities. The deal will integrate Sengenics' KREX™ immunoproteomics and i-OME™ Discovery platform with Standard BioTools' SomaScan/proteomics offerings to enhance biomarker discovery and accelerate drug development.

Illumina Acquires Fluent BioSciences

July 9, 2024

Biotechnology

Illumina, Inc. has acquired Fluent BioSciences to integrate Fluent's PIPseq single-cell technology into Illumina's product portfolio and accelerate its multiomics capabilities. The acquisition, which closed July 9, 2024 and was funded with cash on hand, brings Fluent's accessible, scalable single-cell chemistry and the Fluent team into Illumina to expand end-to-end single-cell solutions for research and applied customers.

Standard BioTools and SomaLogic Planned Merger

December 22, 2023

Healthcare Services

SomaLogic, Inc. announced a proposed merger with Standard BioTools Inc., but several SomaLogic shareholders publicly urged a “no” vote. Tikvah Management and Madryn Asset Management criticized the merger on grounds including alleged undervaluation, process and disclosure concerns, and quality of Standard BioTools’ business and balance sheet.

Pacific Biosciences Acquires Omniome

July 20, 2021

Biotechnology

Pacific Biosciences (PacBio) signed a definitive agreement to acquire San Diego-based Omniome for approximately $600 million in upfront consideration (9.4 million PacBio shares plus $300 million cash) plus up to $200 million in cash and stock tied to milestones, valuing the deal at about $800 million. The deal — supported by a concurrent $300 million PIPE financing — brings Omniome’s high-accuracy short-read Sequencing-by-Binding technology into PacBio’s portfolio of high-accuracy long-read SMRT sequencing systems to expand PacBio’s capabilities and address high-growth clinical markets such as oncology, transcriptomics and NIPT.

Twist Bioscience Acquires iGenomX

June 30, 2021

Biotechnology

Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.

Affymetrix Acquires Panomics for Approximately $73M

November 11, 2008

Biotechnology

Affymetrix Inc. agreed to acquire Panomics Inc., a Fremont, California–based provider of low- to mid-plex genetic and protein assay products, for approximately $73 million in cash. The purchase is intended to expand Affymetrix's product portfolio and enable a more complete genetic-analysis workflow—linking whole-genome microarray studies with targeted Panomics assays—and is expected to close by the end of 2008 subject to customary conditions.